Total Payments
$2,855
2024 Payments
$182.24
Companies
24
Transactions
140
Medicare Patients
4,501
Medicare Billing
$1.1M
Payment Breakdown by Category
Food & Beverage$2,723 (95.4%)
Education$132.43 (4.6%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,723 | 137 | 95.4% |
| Education | $132.43 | 3 | 4.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ViiV Healthcare Company | $394.05 | 17 | $0 (2023) |
| Merck Sharp & Dohme LLC | $376.83 | 21 | $0 (2022) |
| Melinta Therapeutics, LLC | $348.15 | 18 | $0 (2021) |
| Gilead Sciences, Inc. | $307.16 | 17 | $0 (2024) |
| Astellas Pharma US Inc | $258.40 | 8 | $0 (2024) |
| Allergan, Inc. | $200.86 | 9 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $199.33 | 8 | $0 (2024) |
| Insmed, Inc. | $128.95 | 7 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $106.82 | 7 | $0 (2020) |
| ABBVIE INC. | $104.87 | 7 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $182.24 | 7 | Gilead Sciences, Inc. ($64.43) |
| 2023 | $192.50 | 9 | Takeda Pharmaceuticals U.S.A., Inc. ($114.42) |
| 2022 | $208.62 | 12 | ViiV Healthcare Company ($73.20) |
| 2021 | $544.78 | 26 | ViiV Healthcare Company ($257.57) |
| 2020 | $285.69 | 19 | Merck Sharp & Dohme Corporation ($66.18) |
| 2019 | $362.66 | 24 | Paratek Pharmaceuticals, Inc. ($62.82) |
| 2018 | $428.66 | 23 | Melinta Therapeutics, Inc. ($254.72) |
| 2017 | $650.23 | 20 | Astellas Pharma US Inc ($214.87) |
All Payment Transactions
140 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $30.18 | General |
| Category: IMMUNOLOGY | ||||||
| 12/10/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $26.22 | General |
| Category: Respiratory | ||||||
| 05/14/2024 | PFIZER INC. | PANZYGA (Biological), CUTAQUIG | Food and Beverage | In-kind items and services | $18.49 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 03/07/2024 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $14.51 | General |
| Category: IMMUNOLOGY | ||||||
| 03/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.86 | General |
| 02/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.57 | General |
| 02/06/2024 | Astellas Pharma US Inc | Cresemba (Drug) | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: Infectious Diseases | ||||||
| 11/21/2023 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: IMMUNOLOGY | ||||||
| 11/16/2023 | ABBVIE INC. | DALVANCE (Drug), AVYCAZ, TEFLARO | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/29/2023 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $30.45 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2023 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: IMMUNOLOGY | ||||||
| 08/25/2023 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $33.04 | General |
| Category: IMMUNOLOGY | ||||||
| 08/07/2023 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/10/2023 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: HIV | ||||||
| 03/07/2023 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $12.99 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/07/2023 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: HIV | ||||||
| 12/15/2022 | KCI USA, Inc. | 3M Cavilon (Device), ACTIV.A.C., V.A.C. DERMATAC | Food and Beverage | Cash or cash equivalent | $12.46 | General |
| Category: Skin Integrity | ||||||
| 12/12/2022 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 09/26/2022 | Insmed, Inc. | Arikayce (Drug) | Education | In-kind items and services | $16.24 | General |
| Category: Respiratory | ||||||
| 09/17/2022 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: HIV | ||||||
| 09/08/2022 | Ferring Pharmaceuticals Inc. | — | Food and Beverage | In-kind items and services | $16.74 | General |
| 08/11/2022 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), ISENTRESS, DELSTRIGO | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 08/09/2022 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: HIV | ||||||
| 06/14/2022 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $20.30 | General |
| Category: HIV | ||||||
| 04/12/2022 | KCI USA, Inc. | 3M Coban (Device), ACTIV.A.C., V.A.C. DERMATAC | Food and Beverage | Cash or cash equivalent | $22.04 | General |
| Category: Tapes and Wraps | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 1,287 | 75,787 | $739,523 | $297,887 |
| 2022 | 17 | 1,188 | 14,367 | $738,976 | $327,320 |
| 2021 | 16 | 1,049 | 108,403 | $597,127 | $216,621 |
| 2020 | 14 | 977 | 6,985 | $573,871 | $232,299 |
Total Patients
4,501
Total Services
205,542
Medicare Billing
$1.1M
Procedure Codes
67
All Medicare Procedures & Services
67 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0875 | Injection, dalbavancin, 5 mg | Office | 2023 | 14 | 7,450 | $171,350 | $81,105 | 47.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 244 | 726 | $114,706 | $41,787 | 36.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 145 | 358 | $83,361 | $34,608 | 41.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 57 | 532 | $76,608 | $26,749 | 34.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 150 | 365 | $55,480 | $25,270 | 45.5% |
| 97597 | Removal of tissue from wound, 20.0 sq cm or less | Office | 2023 | 32 | 214 | $42,540 | $16,648 | 39.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 154 | 162 | $47,446 | $15,970 | 33.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 52 | 146 | $32,120 | $13,340 | 41.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 95 | 99 | $43,857 | $13,259 | 30.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 72 | 72 | $23,976 | $8,967 | 37.4% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 32 | 212 | $13,356 | $4,720 | 35.3% |
| J1335 | Injection, ertapenem sodium, 500 mg | Office | 2023 | 14 | 292 | $7,551 | $3,002 | 39.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 21 | $6,216 | $2,873 | 46.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 23 | 60 | $5,520 | $2,619 | 47.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 100 | 272 | $3,601 | $2,235 | 62.1% |
| J0878 | Injection, daptomycin, 1 mg | Office | 2023 | 12 | 63,350 | $5,968 | $2,089 | 35.0% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 18 | 18 | $2,826 | $1,199 | 42.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 21 | 22 | $1,826 | $875.82 | 48.0% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 13 | 1,292 | $1,090 | $508.83 | 46.7% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 22 | 124 | $124.00 | $63.29 | 51.0% |
| J0875 | Injection, dalbavancin, 5 mg | Office | 2022 | 22 | 10,800 | $210,836 | $119,237 | 56.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 214 | 710 | $111,998 | $39,933 | 35.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 149 | 424 | $64,448 | $29,959 | 46.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 131 | 294 | $64,710 | $29,573 | 45.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 55 | 478 | $68,832 | $26,087 | 37.9% |
About Dr. Adam Pettigrew, M.D
Dr. Adam Pettigrew, M.D is a Infectious Disease healthcare provider based in Roswell, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/21/2013. The National Provider Identifier (NPI) number assigned to this provider is 1902148539.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Pettigrew, M.D has received a total of $2,855 in payments from pharmaceutical and medical device companies, with $182.24 received in 2024. These payments were reported across 140 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($2,723).
As a Medicare-enrolled provider, Pettigrew has provided services to 4,501 Medicare beneficiaries, totaling 205,542 services with total Medicare billing of $1.1M. Data is available for 4 years (2020–2023), covering 67 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Roswell, GA
- Active Since 03/21/2013
- Last Updated 07/06/2018
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1902148539
Products in Payments
- Baxdela (Drug) $270.40
- DOVATO (Drug) $224.97
- CUVITRU (Biological) $159.11
- CABENUVA (Biological) $150.49
- DALVANCE (Drug) $145.20
- Cresemba (Drug) $143.33
- AVYCAZ (Drug) $136.67
- Arikayce (Drug) $128.95
- DIFICID (Drug) $109.94
- NUZYRA (Drug) $106.82
- ISENTRESS (Drug) $100.62
- MINOCIN IV (Drug) $98.61
- ZEPATIER (Drug) $95.96
- GATTEX (Drug) $59.97
- PIFELTRO (Drug) $59.30
- Vabomere (Drug) $45.71
- Xerava (Drug) $45.02
- Fetroja (Drug) $37.17
- PREZISTA (Drug) $23.95
- TEFLARO (Drug) $23.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Roswell
Rabiul Alam, Md, MD
Infectious Disease — Payments: $8,387
Infectious Disease $8,387
Manuel Castro-Borobio, M.d, M.D
Infectious Disease — Payments: $8,138
Infectious Disease $8,138
Dr. Titu Das, Md, MD
Infectious Disease — Payments: $5,503
Infectious Disease $5,503
Dr. Manuel Rodriguez, D.o.,M.s., M.p.h, D.O.,M.S., M.P.H
Infectious Disease — Payments: $4,251
Infectious Disease $4,251
Dr. David Dickensheets, M.d, M.D
Infectious Disease — Payments: $1,239
Infectious Disease $1,239
Dr. Michael Dailey, M.d, M.D
Infectious Disease — Payments: $1,077
Infectious Disease $1,077